Staidson (Beijing) BioPharmaceuticals Co., Ltd.
Shenzhen Stock Exchange 300204.SZ
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2023: USD 14.56 M
-
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 12.13 M, a -3.21% change year over year.
-
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 12.53 M, a 35.17% change year over year.
-
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 9.27 M, a 32.24% change year over year.
-
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 7.01 M, a -40.95% change year over year.
| Date | Total Non-Current Liabilities | Shareholders' Equity | Other Liabilities | Total Liabilities |
|---|
Don’t Miss A Beat
| CEO | Mr. Wang Chao |
| IPO Date | April 15, 2011 |
| Location | China |
| Headquarters | No. 36, Jinghai Er Road |
| Employees | 555 |
| Sector | Health Care |
| Industries | |
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases. The company has a strategic collaboration with Pivotal S.L. to assess BDB-001, a monoclonal anti-C5a antibody, in a clinical trial in Europe in progressive severe COVID-19 patients caused by SARS-CoV-2. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.
Past 5 years
StockViz Staff
January 31, 2025
Any question? Send us an email